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Abstract
Primary Amoebic Meningoencephalitis (PAM) is caused by Naegleria fowleri, a free-living
amoeba that occasionally infects humans. While considered “rare” (but likely underreported)
the high mortality rate and lack of established success in treatment makes PAM a particu-
larly devastating infection. In the absence of economic inducements to invest in develop-
ment of anti-PAM drugs by the pharmaceutical industry, anti-PAM drug discovery largely
relies on drug ‘repurposing’—a cost effective strategy to apply known drugs for treatment of
rare or neglected diseases. Similar to fungi, N. fowleri has an essential requirement for
ergosterol, a building block of plasma and cell membranes. Disruption of sterol biosynthesis
by small-molecule inhibitors is a validated interventional strategy against fungal pathogens
of medical and agricultural importance. The N. fowleri genome encodes the sterol 14-
demethylase (CYP51) target sharing ~35% sequence identity to fungal orthologues. The
similarity of targets raises the possibility of repurposing anti-mycotic drugs and optimization
of their usage for the treatment of PAM. In this work, we (i) systematically assessed the
impact of anti-fungal azole drugs, known as conazoles, on sterol biosynthesis and viability
of cultured N. fowleri trophozotes, (ii) identified the endogenous CYP51 substrate by mass
spectrometry analysis of N. fowleri lipids, and (iii) analyzed the interactions between the
recombinant CYP51 target and conazoles by UV-vis spectroscopy and x-ray crystallogra-
phy. Collectively, the target-based and parasite-based data obtained in these studies vali-
dated CYP51 as a potentially ‘druggable’ target in N. fowleri, and conazole drugs as the
candidates for assessment in the animal model of PAM.
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Author summary
The free-living amoeba, Naegleria fowleri, is commonly found in water sources including
swimming pools having inadequate levels of chlorine, lakes, and rivers. N. fowleri can act
as an opportunistic pathogen causing severe brain injury called Primary Amebic Menin-
goencephalitis (PAM), often in healthy children and young adults. With a fatality rate
over 97%, N. fowleri is considered one of the most deadly human pathogens. Despite the
fact that precious lives are lost annually, N. fowleri infection is rare and economic incen-
tives to invest in development of anti-PAM drugs by the pharmaceutical industry are
lacking. In the absence of economic inducements, drug ‘repurposing’ is a cost effective
strategy for re-profiling known drugs for the treatment of neglected diseases. The similar-
ity between pathogenic fungi and free-living amoebae in the sterol biosynthesis pathway
encouraged us to assess anti-mycotic drugs, clinically-approved for treatment of a variety
of fungal diseases, for anti-Naegleria activity. Carrying out biochemical studies and x-
ray-crystallography of the target enzyme, we demonstrated that azole anti-fungal drugs,
known as conazoles, disrupt sterol biosynthesis in amoebae by competing with the natural
substrate for binding in the active site of the sterol 14-demethylase (CYP51). Disruption
of sterol biosynthesis leads to a rapid death of pathogenic amoebae.
Introduction
The amphizoic amoeba (existing both in free-living and parasitic forms), Naegleria fowleri is
commonly found in water resources such as swimming pools having inadequate levels of chlo-
rine, lakes and rivers. It feeds mostly on bacteria, but can also act as an opportunistic pathogen
causing infection of the central nervous system (CNS) of humans and animals.[1] N. fowleri
usually infects people when contaminated water enters the body through the nose. Following
infection, N. fowleri infiltrates the nasal mucosa and passes along the olfactory neuroepithelial
route to invade the brain. N. fowleri causes severe primary amebic meningoencephalitis
(PAM) resulting in cerebral edema and destruction of brain tissue, mostly in healthy children
and young adults.[2] PAM due to N. fowleri has a worldwide distribution although it occurs
most frequently in tropical areas and during hot summer months.[3] Infection is considered
rare in the United States (0–8 infections per year)[4] but PAM cases may go unnoticed among
other infections, particularly in the developing countries.[1] Noteworthy, PAM is not on the
National Notifiable Diseases Surveillance list; thus, reporting of the national incidence of PAM
by the US Centers for Disease Control and Prevention (CDC) depends on individual state
health departments to report diseases voluntarily. Despite modern improvements in antimi-
crobial therapy and supportive medical care, the fatality rate associated with N. fowleri PAM is
>97%.[4] The disease is particularly problematic due to both its rapid onset and the lack of
effective treatments.[5] Currently, there is no single, proven, evidence-based treatment with a
high probability of cure. The full recovery of a patient in the summer of 2013, after 35 years
without a Naegleria survivor in the US, was attributed to early diagnosis and treatment, and
the use of combination therapy including the investigational drug miltefosine and induced
hypothermia.[6] In the absence of data to estimate the true risk of PAM or to set up and rein-
force the measurable standards to protect the human population, early diagnosis and aggres-
sive antimicrobial treatment remain the only option to treat the disease.
The CDC-recommended treatment for patients suspected of PAM currently includes com-
bination therapy consisting of anti-mycotic drugs amphotericin B (AmpB) and fluconazole,
antibiotics azithromycin and rifampin, the investigational anti-cancer agent miltefosine and,
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finally, an anti-inflammatory drug, dexamethasone, to reduce the cerebral edema.[1] AmpB, a
cornerstone of PAM therapy and a standard of care for CNS infections caused by molds, acts
via binding ergosterol in cell membranes causing rapid leakage of monovalent ions leading to
cell death.[7] Clinical use of AmpB is limited due to its toxicity, including acute infusion-
related reactions and dose-related nephrotoxicity.[1] Fluconazole is another anti-mycotic drug
that acts via a different mechanism. Fluconazole depletes the ergosterol pool by blocking
removal of the methyl group at C-14 position of a biosynthetic precursor catalyzed by sterol
14-demethylase (CYP51).[8–11] Fluconazole belongs to the ‘conazole’ pedigree of antifungal
agents targeting CYP51.[12] This drug class also includes miconazole, ketoconazole, voricona-
zole and itraconazole that were previously reported to exhibit amoebicidal effect against N.
fowleri in vitro.[13–17] Fluconazole and miconazole have also been used in combination with
other drugs as part of treatment regimens in human PAM patients.[6, 18, 19]
De novo sterol biosynthesis from squalene takes place in most high eukaryotes (although it
is lost in certain lineages, e.g. insects and worms) and also in lower eukaryotes with an aerobic
life style.[20] The latter include human pathogens such as fungi, kinetoplastids and free-living
amoebae. Disruption of sterol biosynthesis by small-molecule inhibitors is a validated inter-
ventional strategy against fungal pathogens of medical and agricultural importance. CYP51 is
one of the most extensively exploited drug targets for the development of anti-fungal agents.
Kinetoplastids are major parasite targets for the development of CYP51 inhibitors outside tra-
ditional antifungal drug discovery programs.[21]
Similar to fungi and kinetoplastids, amoebae from the genera Naegleria and Acanthamoeba
have an essential requirement for ergosterol.[22–24] In contrast to the lanosterol route in
fungi and kinetoplastids,[25] biosynthesis of ergosterol in amoebae occurs via cycloartenol, a
sterol biosynthetic precursor typical of photosynthetic organisms, ie., algae and plants.[22–24]
N. fowleri genome encodes CYP51 (NfCYP51; AmoebaDB accession number NF0102700)
sharing ~35% sequence identity to human, fungal and kinetoplastid orthologues. Higher
sequence identity to plant (<40%), Acanthamoeba (42%), and a non-pathogenic Naegleria gru-
beri (86%) is consistent with the ‘plant-like’ substrate specificity of NfCYP51.[23] The similar-
ity of targets raises the possibility of ‘repurposing’ anti-mycotic drugs, clinically-approved
against a variety of fungal diseases, and optimization of azole-based PAM therapy for treat-
ment of PAM.
In this work, we (1) chemically validate sterol biosynthesis pathway as a “druggable” target
in N. fowleri and (2) systematically assess the efficacy of the anti-fungal azole drugs, known as
conazoles (including the latest additions to the armamentarium of the anti-fungal drugs, posa-
conazole and isavuconazole) versus both the whole organism and the recombinant molecular
target. In the course of the studies, we (i) validated NfCYP51 as an essential biosynthetic
enzyme in N. fowleri, (ii) determined the endogenous NfCYP51 substrate, and (iii) character-
ized drug-target interactions by UV-vis spectroscopy and protein x-ray crystallography.
Results and discussion
Anti-proliferative effect of conazoles in vitro
An assay previously developed and validated [26] was used to assess anti-proliferative activity
of the conazoles presented in Fig 1. In this assay, conazoles demonstrated anti-N. fowleri activ-
ity in a broad range of concentrations—from an EC50 of 13.9 μM (fluconazole) to0.01 μM
(for itraconazole and posaconazole) (Table 1). Notably, in vitro potency of all conazole drugs
exceeded that of miltefosine; itraconazole and posaconazole were an order of magnitude more
potent than AmpB, while ketoconazole and isavuconazole were equipotent to AmpB. Across
the board, anti-Naegleria potency of conazoles increased with the increase of the molecular
CYP51 is essential enzyme in Naegleria fowleri trophozoites
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Fig 1. Azole antifungal drugs also known as conazoles.
https://doi.org/10.1371/journal.pntd.0006104.g001
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weight (MW), from fluconazole (306.3 g/mol) to itraconazole (705.6 g/mol). Between 340 g/
mol and 450 g/mol, anti-proliferative activity of conazoles correlated with lipophilicity per
non-hydrogen atom expressed as logP/MW values—more lipophilic drugs demonstrated
higher potency (Table 1). This trend is explained by the hydrophobicity of the NfCYP51 bind-
ing site favoring binding of lipophilic molecules, as demonstrated by the co-crystal structures
determined in this work. The potency observed for fluconazole (EC50 of 13.9 μM, equivalent of
4.3 mg/ml) was lower than the MIC50 values of 0.5–2.0 mg/ml reported elsewhere for N. fowleri
isolates, either from natural water sources[16] or from patients who had died of PAM.[15]
Growth inhibition as a function of time
To answer the question of how fast CYP51 inhibitors kill N. fowleri, we measured growth inhibi-
tion dose-response to posaconazole at different time points. N. fowleri trophozoites were exposed
to a single dose of posaconazole serially diluted in 96-well format from 25 μM to 0.008 μM in
0.2% sulfobutylether-β-cyclodextrin (SBE-β-CD), also known as Captisol. SBE-β-CD is used as an
excipient (a formulating agent) to increase the solubility of poorly soluble drugs, including posa-
conazole in the Noxafil intravenous formulation (Merck).[31] Growth inhibition curves con-
structed for different time points (Fig 2) demonstrate an inhibitory effect of posaconazole at the
highest concentrations as early as 8 h post-exposure. Inhibition reaches 40% at 16 h post-expo-
sure, ~90% at 24 h (EC50 of 2.7 nM) and maximizes at 48 h (EC50 of 4.9 nM).
Target engagement in N. fowleri trophozoites
Impact of posaconazole on sterol biosynthesis. To chemically validate NfCYP51 as a
therapeutic drug target, we analyzed metabolites accumulated in N. fowleri in response to
posaconazole. Lipids extracted from 20 or 50 million trophozoites treated with 0.1% DMSO,
0.2 μM AmpB or 0.2 μM posaconazole for 24 hours were subjected to gas chromatography-
mass spectrometry (GC-MS) analysis. The sterol identities were assigned based on relative
chromatographic behavior, the characteristic molecular masses and electron ionization (EI)
fragmentation patterns of free sterols (Fig 3) or of the trimethylsilyl (TMS)-derivatized sterols
(S1 Fig).
Table 1. Inhibition of N. fowleri with conazoles.
Drugs MW, g/mol logP logP/MW,
×103
logD
at pH 7.4
EC50, μM
Itraconazole 705.6 5.7a 8.1 >5b 0.01
Posaconazole 700.8 5.5a 7.8 2.15b 0.01
Ketoconazole 531.4 4.4a 8.3 3.7[27] 0.1±0.04
Isavuconazole 437.5 3.1c 7.1 3.13 0.1±0.04
Miconazole 416.1 6.1a 14.6 6.3[28] 2.0±0.04
Voriconazole 349.3 1.0a 2.9 1.8b 76% at 25 μM
Clotrimazole 344.8 6.1a 17.7 5.2[29] 0.6±0.03
Fluconazole 306.3 0.4a 1.3 0.5b 13.9±0.01
Standards of care
Amphotericin B 924.1 0.8a -2.8b 0.1±0.01
Miltefosine 407.6 3.4c 4.0c 54.5±0.01
aexperimental logP values, as reported by the Drug Bank (www.drugbank.ca)
bReviewed elsewhere[30]
ccalculated logP and logD values are from EMBL-EBI (www.ebi.ac.uk)
https://doi.org/10.1371/journal.pntd.0006104.t001
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Similar to other previously characterized free-living amoebae of Naegleria and Acantha-
moeba genera,[22–24] sterol biosynthesis in N. fowleri proceeds from cycloartenol (15) via
31-norlanosterol (14) to ergosterol (5) (Fig 4). Ergosterol and its biosynthetic precursor
ergosta-5,7-dienol (7) are the two most abundant endogenous sterols dominating lipid extracts
of DMSO-treated N. fowleri (48% of total sterol mass), whereas 4-monomethyl-, 4,4-dimethyl-
and 14α-methylsterols are represented sparsely (Table 2). Cholesterol (1) constituting about
25% of sterol mass in both DMSO- and posaconazole-treated samples (Table 2), is likely
ingested from the growth media containing fetal bovine serum (FBS) and liver extract. AmpB,
a drug with a different mechanism of action used as a negative control, did not perturb the
native sterol pattern (S1 Fig).
Upon treatment with posaconazole, the ratio of metabolites changed dramatically. The total
content of the 14α-methylsterols increased from 6.5% to 49.1%, with the major accumulated
intermediate being 31-norlanosterol, followed by its C24-C25 hydrogenated product, 4,14-
dimethylcholest-8-enol (9) (Table 2). Removal of the 4β-methyl group was unaffected by
posaconazole, meaning that it likely occurs prior to 14-demethylation. Based on these data,
Fig 2. Posaconazole growth inhibition curves at different time points.
https://doi.org/10.1371/journal.pntd.0006104.g002
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31-norlanosterol serves an endogenous substrate of NfCYP51. Accumulation of the 4α-
methylsterols in posaconazole-treated N. fowleri—increase from 6.8% to 48.5%—indicates that
removal of the 4α-methyl group occurs downstream of CYP51. Finally, both C24 methylation
catalyzed by sterol C24-methyltransferase, double bond isomerization catalyzed by sterol Δ8-
Δ7-isomerase (reaction 4!8), and C22-C23 bond desaturation catalyzed by Δ22-desaturase,
also occur downstream of CYP51 (reaction 7!5) (Fig 4).
Steryl esters. Along with the sterol intermediates, multiple steryl esters were detected in
the lipid extracts (Fig 3). Steryl moieties were identified by the molecular masses calculated
from the m/z values of the [M-ROH]+ fragments compared with the fragmentation patterns to
Fig 3. Gas chromatography separation of the total sterol fractions extracted from N. fowleri
trophozoites. Chromatogram fragments from the non-derivatized DMSO- (black trace) and posaconazole
(POS)-treated (red trace) sterol extracts are shown. Peaks are labeled according to Table 2. The content of
31-norlanosterol (14) remarkably increased in posaconazole-treated samples.
https://doi.org/10.1371/journal.pntd.0006104.g003
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the sterol acetate standards in the NIST database (Table 3). The fatty acid identities of steryl
esters have not been analyzed due to limited sample size. Upon exposure to posaconazole, the
steryl ester pool declined compared to the free sterols, as judged by the steryl ester/free sterol
ratio (Table 3). The composition of the steryl ester pool also changed. The notable increase in
cholesteryl ester from 4.3 to 13.6% may be an attempt to compensate for the deficit of endoge-
nous sterols. On the contrary, the content of squalene dropped in the posaconazole-treated
Fig 4. The mainstream of the ergosterol biosynthesis cascade in N. fowleri. Sterols are numbered
according to the Table 2.
https://doi.org/10.1371/journal.pntd.0006104.g004
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sample from 5.5 to 1.5% suggesting a regulatory loop signaling excess of the downstream
intermediates.
Table 2. Sterol composition in N. fowleri treated with 0.1% DMSO or 0.2 μM posaconazole.
Sterols RTTca % Composition
DMSO Posaconazole
4-Desmethylsterols (% of total) 90.0 50.5
1 Cholesterol 1 25.6 26.1
2 7-Dehydrocholesterol 1.044 12.5 3.9
3 Lathosterol 1.061 0.8
4 Zymosterolb 1.068 0.4
5 Ergosterol 1.114 26.7 14.2
6 Ergost-5-enol 1.136 1.4 0.7
7 Ergosta-5,7-dienol 1.202 21.3 5.7
8 Ergost-7-enol 1.22 1.2
4-Monomethylsterols 6.8 48.5
9 4α,14α-Dimethylcholest-8-enol 1.082 1.1 15.5
10 4α-Methylergost-8-enol 1.095 3.5 0.4
14 31-Norlanosterol 1.143 2.2 29.7
11 Δ7-31-norlanosterol 1.238 2.9
4,4-Dimethylsterols 3.2 1.0
12 24-Dihydrolanosterol 1.304 0.2 0.2
13 24-Dihydrocycloartenol 1.324 1.1
14 Parkeol 1.384 0.1
15 Cycloartenol 1.406 2.0 0.7
14α-Methylsterols 6.5 49.1
Δ24(25)-sterols 8.1
arelative retention time compared to cholesterol
bin bold are highlighted sterols constituting the mainstream of biosynthesis cascade in Fig 4
https://doi.org/10.1371/journal.pntd.0006104.t002
Table 3. Composition of the steryl ester pool in N. fowleri.
Steryl estera [M-ROH]+ RT (min) % of Total
DMSO Posaconazole
7-Dehydrocholesteryl ester-1 366 9.3 6.1 5.7
Squaleneb 410 9.5 5.5 1.5
Ergosteryl ester 378 9.7 15.9 16.1
5,7,24-Triene-ergosteryl ester-1 378 10.1 11.6 15.6
5,7-Diene-ergosteryl ester-1 380 10.2 13.0 8.2
Cholesteryl ester 368 10.5 4.3 13.6
5,7-Diene-ergosteryl ester-2 380 10.7 12.8 8.4
7-Dehydrocholesteryl ester-2 366 11.1 4.6 3.6
5,7,24-Triene-ergosteryl ester-2 378 11.7 12.6 18.2
5,7-Diene-ergosteryl ester-3 380 12.5 13.5 9.1
Ratio (steryl ester/free sterol)c 0.24 0.15
aThe fatty acid moieties were not identified (the MS scan range was from 50 to 450 amu)
bNot a steryl ester.
cThe ratio was calculated by dividing a sum of total ion count peak areas of the steryl esters by that of free sterols.
https://doi.org/10.1371/journal.pntd.0006104.t003
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Impact of posaconazole on the N. fowleri cell ultrastructure
DMSO-treated N. fowleri trophozoites displayed normal morphology with several food vacu-
oles, mitochondria, lipid droplets and a nucleus containing one large nucleolus (Fig 5A). Lipid
droplets serve as the energy and carbon reservoirs in all domains of life. From analysis of
another free-living amoeba, Dictyostelium discoideum, reported elsewhere,[32] we know that
amoeba lipid droplets consist of a hydrophobic core of triglycerides, steryl esters and free ste-
rols surrounded by one leaflet derived from the endoplasmic reticulum membrane to which a
specific set of proteins is bound. Between 24 and 48 hours of undisrupted growth, N. fowleri
lipid droplets increased in number and density (Fig 5C).
Treatment with posaconazole led to disorganization of N. fowleri membranes, swelling of
mitochondria and appearance of multiple autophagic vacuoles engulfing organelle debris and
myelin figures (loops of membranes), indicative of disruption of lipid metabolism. (Fig 5B
and 5D). Similar ultrastructural alterations were previously reported in N. fowleri treated with
AmpB, including mitochondrial abnormalities and an increase in autophagic vacuoles with
myelin-like membranous whorls.[33] AmpB-treated amoebae also had abnormally shaped
nucleus and an increase in rough and smooth endoplasmic reticulum membranes,[33] alter-
ations not observed with posaconazole. Finally, lipid droplets of the AmpB-treated amoebae
were clustered and enclosed in membranous sheet, whereas treatment with posaconazole in
these studies resulted in dispersion of lipid droplets throughout the cell with decrease in size
and density.
Consistent with the rate of growth inhibition experiment (Fig 2), significant differences in
cell ultrastructure are observed after 24 h of posaconazole exposure and no further differences
were recorded between 24 h and 48 h of treatment (Fig 5B vs. Fig 5D). This observation dis-
tinguishes N. fowleri from kinetoplastid parasites where CYP51 inhibitors are notoriously
slow-acting.[34] In T. cruzi, ultrastructural alterations and increase in autophagic vacuoles are
first observed after 72–96 h drug exposure when lipid droplets are largely exhausted.[35, 36] In
N. fowleri, dispersed lipid droplets albeit of reduced density are present after 48 h in signifi-
cantly damaged Naegleria cells. Similar lipid accumulation after posaconazole exposure is
observed in Leishmania amazonensis, both by TEM and fluorescent staining by Nile Red.[37]
Interaction of conazoles with the recombinant NfCYP51 target by UV-vis
spectroscopy
The recombinant NfCYP51 was authenticated and the drug-target interactions were character-
ized by UV-vis spectroscopy. The ferric, Fe3+, spectrum of NfCYP51 is typical of that of a low-
spin P450 (CYP) with a Soret band at 417 nm, while that of the dithionite reduced ferrous,
Fe2+, species has a Soret band of 411 nm (Fig 6A). The 449 nm Soret band of the dithionite
reduced and CO bound NfCYP51 is consistent with that of functional CYP enzymes (Fig 6A,
inset). Upon binding to P450, a heterocyclic drug replaces the heme axial water ligand result-
ing in a red-shift of the iron Soret band, known as type II.[38] Conazoles bound to NfCYP51
produced type II low-spin difference spectra with a trough at 411 nm and a peak at 430 nm,
indicative of azole coordination to the heme iron (Fig 6B). 31-Norlanosterol binding produced
a type I high-spin difference spectrum with a peak at 388 nm and a trough at 418 nm (Fig 6B),
resulting from the expulsion of water molecule ligand from the iron coordination sphere by
the incoming substrate.[38] The dissociation constant, KD, of 124±25 nM, was calculated for
31-norlanosterol by fitting plotted spectroscopic data to the standard Michaelis-Menten or
Morrison binding equations (Fig 6C), both yielding the same KD value. The dissociation con-
stants for conazoles could not be calculated by this method due to enzyme saturation reached
after the addition of one molar equivalent of a conazole drug to 0.5 μM NfCYP51, as illustrated
CYP51 is essential enzyme in Naegleria fowleri trophozoites
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Fig 5. Ultrastructural analysis of posaconazole-treated N. fowleri by transmission electron
microscopy (TEM). 0.1% DMSO-treated controls (A: A1-A3, 24 h; and C: C1-C3, 48 h, show several food
vacuoles (V), mitochondria (M), nucleus (N) and lipid droplets (L). Exposure to 0.2 μM posaconazole (B:
B1-B3, 24 h; D: D1-D3, 48 h) led to mitochondrial swelling, accumulation of atypical lipid droplets, alteration of
nuclear membrane and appearance of autophagic vacuoles (A) engulfing organelle debris and myelin figures
(MF). Bar = 500 nm.
https://doi.org/10.1371/journal.pntd.0006104.g005
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for fluconazole and posaconazole (Fig 6D). When sub-stoichiometric concentrations of drugs
were titrated into the enzyme solution, a linear increase in signal was observed for all conazoles
up until the equivalence point, after which no further increase in signal was detected. Dilution
of NfCYP51 below 0.5 μM resulted in a substantial drop in signal-to-noise ratio in the re-
corded spectra. From the UV-vis data, we conclude that even the smallest azole drug, flucona-
zole, binds NfCYP51 with affinity roughly an order of magnitude exceeding that of natural
substrate, 31-norlanosterol. The binding superiority of the azole drugs over natural substrate is
achieved due to the formation of the coordination bond between an aromatic nitrogen of the
azole heterocycle and the heme iron (Fig 7A–7D).
Drug-target interactions by x-ray crystallography
Overall structure. To further characterize drug-target interactions, we have screened con-
azoles for co-crystallization propensity with the NfCYP51 target and determined the co-crystal
structures of NfCYP51 bound to five conazole drugs: posaconazole (1.71 Å), ketoconazole
(1.87 Å), itraconazole (2.6 Å), voriconazole (2.4 Å) and fluconazole (2.7 Å) (Table 4). All cona-
zoles form a coordination bond to the heme iron via an aromatic nitrogen of the heterocycle
moiety (Fig 7A–7D). The overall protein scaffold of NfCYP51 is similar to that of previously
characterized CYP51 from other eukaryotes with the qualification that certain secondary
structure elements sample multiple conformations spontaneously or in response to the incom-
ing ligand.[39–41] A number of the co-crystal structures for human,[42] yeast,[43, 44] fungi
Fig 6. Spectroscopic analysis of recombinant NfCYP51. (A) Absolute UV-visible spectra of 3.5 μM
purified recombinant NfCYP51: ferric, Fe3+,—solid line, ferrous, Fe2+,—dashed line. Inset: Fe2+- Fe2+CO
difference spectra. (B) Type I (31-norlanosterol) and type II (posaconazole) difference spectra both added in
500 nM increments to 3.5 μM NfCYP51. (C) Binding isotherm of 31-norlanosterol added in 25 nM increments
to 0.2 μM NfCYP51 and absorbance difference spectra (Inset). (D) Binding isotherms of posaconazole and
fluconazole, both added in 50 nM increments to 0.5 μM NfCYP51, show a linear increase in signal up until the
equivalence point, after which no further increase in signal was detected.
https://doi.org/10.1371/journal.pntd.0006104.g006
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[45, 46] and kinetoplastid[21] orthologues reported to date point at the BC- and FG-loops and
the F- and G-helices (nomenclature introduced by Poulos et al.[47]), as the most conforma-
tionally variable structural elements whose concerted motion modulates the size and topology
of the CYP51 binding site.
Drug-target interactions. Both posaconazole and itraconazole (MW ~700 g/mol) occupy
the whole length of the CYP51 hydrophobic tunnel spanning from the heme macrocycle to the
protein surface (Fig 7A). At Pro213, the tunnel turns forcing the inhibitor’s long moiety to
bend at piperazine ring. The bent conformation of posaconazole has been previously reported
in T. brucei CYP51.[48] As evidenced by the Fo-Fc electron density map (S2 Fig), the 2,4-
dichlorophenyl moiety of itraconazole may flip in the vicinity of heme adopting two alternative
conformations. Flipping of the 2,4-difluorophenyl moiety was previously observed in flucona-
zole.[48] The smaller ketoconazole (MW 531 g/mol) also extends into the hydrophobic tunnel
but only to reach Pro213 (Fig 7B). Finally, voriconazole and fluconazole (MW 300–350 g/
mol), bind in vicinity of heme macrocycle and benefit very little from the tunnel space (Fig 7C
and 7D). Well-defined by electron density, the 5-fluoropyrimidinyl moiety of voriconazole
makes a series of contacts within 6 Å of Tyr107, Phe109, Met110, Leu358, Met362 and Leu467,
plus a H-bond to carbonyl oxygen of M360 (3.6 Å) (Fig 7C). The smaller and more hydro-
philic 1,2,4-triazolyl group of fluconazole is less favored by this environment, as evidenced by
Fig 7. NfCYP51-inhibitor binding. (A) Posaconazole (yellow sticks) and itraconazole (black lines) are shown overlapped. Fragment
of the 1.7 Å 2Fo-Fc electron density map countered at 1.σ is shown for posaconazole (cyan mesh). Amino acid residues within 5 Å are
in blue, heme is in spheres. Ketoconazole (B), voriconazole (C) and fluconazole (D) are shown in yellow sticks with the corresponding
map fragments in cyan mesh. In C and D, amino acid contacts only for the inhibitor moiety distant from the heme macrocycle are
shown. Distances are in Angstroms. (E) Amino acid residues within 5 Å of bound posaconazole in NfCYP51 (highlighted in bold) are
propagated to the CYP51 sequences from the indicated species. Residue labeling is according to NfCYP51. Secondary structure
elements on the top are labeled according to the nomenclature introduced elsewhere.[47] The color scheme is according to the side
chains: hydrophilic neutral (cyan), aromatic (purple), hydrophobic (green) and proline (ochre). Residue conservation is indicated by
the color shades, with pale! bright gradient corresponds to conservation levels. Invariant positions are in brightest shades.
https://doi.org/10.1371/journal.pntd.0006104.g007
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the longer distances and the electron density map progressively less defined for the triazole
moiety not involved in the coordination of heme iron (Fig 7D).
Variability of the CYP51 binding site. The first-tier contacts within 5 Å of inhibitors
deduced from the NfCYP51 structure have been projected to the CYP51 sequences of other
human pathogens (Fig 7E). Predominantly aliphatic and aromatic amino acid residues delin-
eate the binding tunnel in CYP51, with only three of them being invariant across the species.
Variable positions with different degree of conservation confer substrate- and inhibitor-bind-
ing specificity to the CYP51 orthologues. Consistent with the biochemical data, phylogenetic
analysis points at ‘plant-like’ substrate specificity of NfCYP51 defined by Phe109 (numbering
is according to NfCYP51) that is only present in the orthologues converting the 4α-mono-
methylsterol substrates, obtusifoliol or 31-norlanosterol. In this regard, Naegleria, Acantha-
moeba and T. brucei group together with plant CYP51 represented in Fig 7E by Arabidopsis
thaliana. The T. cruzi, fungal and mammalian CYP51 having leucine/isoleucine at 109 metab-
olize 4α, β-dimethylated sterol substrates, lanosterol, eburicol and 24,25-dihydrolanosterol.
Another critical sequence variability is mapped to proline 213. A non-conserved proline-
to-histidine substitution in human CYP51 accounts for the host-pathogen selectivity of cona-
zoles. The histidine moiety protruding into the hydrophobic tunnel of human CYP51 inter-
feres with a long substituent of the high MW conazoles. The substantial genetic divergence
between the etiological agents of human diseases require tailored implementation of patho-
gen-specific drug discovery programs utilizing methodologies specific to the targeted
Table 4. Crystallographic data collection and refinement statistics.
Protein NfCYP51 NfCYP51 NfCYP51 NfCYP51 NfCYP51
Ligand
Ligand ID
Posaconazole
X2N
Itraconazole
1YN
Ketoconazole
KKK
Voriconazole
VOR
Fluconazole
TPF
PDB ID 5TL8 6AYC 6AYB 6AY6 6AY4
Data collection
Space group C2 C2 C2 C2 C2
Cell dimensions
a, b, c (Å) 120.0, 55.0, 71.6 120.3, 55.2, 72.4 119.2, 55.3, 71.6 120.2, 55.3, 73.2 122.1, 55.3, 73.5
α, β, γ (˚) 90.0, 100.1, 90.0 90.0, 100.6, 90.0 90.0, 100.1, 90.0 90.0, 100.8, 90.0 90.0, 101.5, 90.0
Molecules in AU 1 1 1 1 1
Wavelength 1.11587 1.11587 1.11587 1.11587 1.11587
Resolution (Å) 1.71 2.60 1.87 2.40 2.70
Rf (%) 4.1 (144.8)a 13.3 (286.5) 20.3 (188.7) 10.9 (136.0) 7.0 (160.4)
I/σI 14.4 (0.62) 7.1 (0.59) 3.79 (0.53) 7.0 (0.47) 7.94 (0.57)
Completeness (%) 98.3 (85.6) 99.7 (99.8) 95.1 (68.4) 97.3 (66.5) 97.7 (99.8)
Redundancy 3.6 (2.4) 6.5 (6.9) 6.0 (4.7) 5.5 (2.2) 2.6 (2.6)
Refinement
No. reflections 47085 13616 34450 17255 12443
Rwork / Rfree (%) 19.5/24.9 21.8/29.0 24.3/28.4 21.9/29.0 25.7/31.3
No. atoms 3799 3731 3712 3660 3670
Wilson 36.1 86.0 42.9 82.1 85.6
Mean B value 39.9 95.1 46.0 85.3 97.8
R.m.s deviations
Bond lengths (Å) 0.018 0.011 0.019 0.009 0.008
Bond angles (˚) 2.002 1.938 1.260 1.005 1.506
aValues for highest-resolution shells are in parentheses
https://doi.org/10.1371/journal.pntd.0006104.t004
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pathogens. For N. fowleri, the crystal structures determined in this work may be indispensable
for designing molecules combining potency against NfCYP51 with brain permeability.
While UV-vis spectroscopy could not prioritize conazoles by binding affinity due to insuffi-
cient sensitivity of the experimental setup, the co-crystal structures unambiguously link the
decline in conazole’s potency to the decrease in a number of drug-target interactions as a func-
tion of MW. The highest MW conazoles, posaconazole and itraconazole, making a large num-
ber of interactions in the CYP51 hydrophobic tunnel, are broad spectrum. Fluconazole, with
the least number of drug-target contacts, is a narrow spectrum antifungal agent with the activ-
ity limited to Candida albicans (but not C. krusei or C. glabrata) and Cryptococcus neoformans.
Despite of being part of the drug formulation used for the treatment of PAM patients, flucona-
zole has the lowest activity against N. fowleri (EC50 of 13.9 μM) among azole drugs. Differences
in the first-tier residues directly contacting fluconazole in N. fowleri and C. albicans (Fig 7E)
may account for the differential activity. Also, high glycine content (positions equivalent to
Ala54, Ala289 and Ala293 in N. fowleri are taken by glycine in C. albicans) may render C. albi-
cans CYP51 more adaptive to fluconazole.
Perspectives of conazoles in the treatment of PAM
Although the potency of some conazoles against cultured N. fowleri was equal or exceeded that
of AmpB (Table 1), to attain parasitological cure in PAM patients, a drug must cross the
blood-brain barrier (BBB). Conazoles exhibit variable physicochemical characteristics and dif-
fer with regard to cerebrospinal fluid (CSF) and brain parenchymal penetration.[30, 49]
Across the board, brain permeability of conazoles is inversely related to the MW and to their
in vitro anti-Naegleria potency. Thus, fluconazole, having the lowest activity against N. fowleri,
is known to rapidly distribute through body tissues, including different CNS compartments,
where it achieves concentrations greater than MIC90 of common fungal pathogens.[49, 50]
The intermediate MW conazoles penetrate CSF and brain tissue to a different extent. Vorico-
nazole brain permeability has been reported in human studies of meningitis patients.[51–53]
Miconazole is effective in treatment of human fungal meningitis not susceptible to AmpB;
high brain concentrations of miconazole are achieved by intrathecal (IT) administration.[54,
55] Rabbit studies have shown that ravuconazole[56] and ketoconazole[57] penetrate brain
tissue; intermediate concentrations of ketoconazole were found in CSF and are modestly
increased in the presence of meningeal inflammation.[57]
Finally, the highest MW conazoles—posaconazole and itraconazole–have CNS pharmaco-
kinetics similar to that of a cornerstone of PAM therapy, AmpB. In rabbit studies, none of
the AmpB formulations produced measurable concentrations in the CSF regardless of CNS
inflammation.[58, 59] At the same time, detectable brain parenchymal AmpB concentrations
were observed even in the absence of CNS infection (3–27% of serum concentrations) and
increased two- to four-fold in presence of infection.[59] Animal model and human studies
reported nearly undetectable CSF concentrations of itraconazole,[60–62] while posaconazole
showed striking differences in the CSF-to-plasma ratios ranging from the below limit of de-
tection to 2.4.[63] Disturbance of the BBB tight junctions by inflammation may facilitate pas-
sage of posaconazole into the CSF.[64] Despite the lack of appreciable CSF concentrations,
itraconazole accumulates in brain parenchyma as an active hydroxylated metabolite at concen-
trations higher than the MIC of the infecting fungi.[65] The ability of itraconazole and posaco-
nazole to accumulate in brain tissue may account for successful use of these drugs for CNS
invasive fungal infections in humans.[57, 66–68] If brain parenchymal kinetics are valid pre-
dictor of antifungal efficacy in the treatment of CNS mycoses compared to CSF concentra-
tions,[49] the same may be true for anti-Naegleria efficacy. Systematic assessment of conazoles
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in an animal model of PAM would single out the most efficacious drug of this class for the
treatment of PAM.
Summary. Based on the collective evidence of the target-based and whole-parasite studies,
we conclude that amoebicidal effect of conazoles in N. fowleri is due to depletion of the ergos-
terol pool concomitant with accumulation in large amounts of sterol intermediates with
molecular structure/physicochemical properties incompatible with normal cell physiology.
Disruption of CYP51 function induces massive autophagocytosis leading to rapid N. fowleri
cell death. These data validate CYP51 as an essential enzyme and potentially a druggable target
in N. fowleri. However, the amoebicidal activity of conazoles is inversely related to their brain
permeability: it increases with the increase of drug molecular weight (MW), reaching low
nanomolar potency for posaconazole and itraconazole. The low anti-N. fowleri activity of the
brain-penetrant fluconazole questions its role in a drug combination currently recommended
by CDC for the PAM treatment.
Materials and methods
Materials
The Naegleria fowleri strain KUL originally isolated from human cerebrospinal fluid in Bel-
gium in 1973[69] was obtained from ATCC. KUL is type 3 strain based on the length of the
internal transcribed spacers 1 (ITS1), with the T at position 31 in the 5.8S rDNA sequence.[3]
Azole inhibitors were purchased from commercial sources: fluconazole from Cayman
Chemical, clotrimazole, miconazole (racemic mix) and voriconazole from Sigma-Aldrich,
ketoconazole and itraconazole from Alfa Aesar, voriconazole and isavuconazole from Stru-
Chem (China). Posaconazole was purified from a Noxafil (Merck) suspension purchased from
a pharmacy, as previously described.[35] Miltefosine and amphotericin B were purchased
from Sigma-Aldrich. Sulfobutylether-β-cyclodextrin (SBE-β-CD), also known as Captisol, was
from MedChem Express and methyl-β-cyclodextrin (M-β-CD) was from Sigma-Aldrich.
31-Norlanosterol was purified from Candida albicans treated with both CYP51 and SMT
inhibitors; the structure of the sterol was authenticated by both the GC-MS and NMR
methods.
Drug stock solutions were freshly made either in DMSO or 40% SBE-β-CD. The DMSO
stock was used for preparation of the electron microscopy and GC-MS samples, while the SBE-
β-CD stock was used for serial dilutions in the growth inhibition experiments. The SBE-β-CD
stock solutions were prepared based on the compositions for the posaconazole intravenous
administration provided in the US Patent 2013/0096053 A1.[31]. Briefly, a 40% solution of
SBE-β-CD was prepared by dissolving 4 grams of SBE-β-CD in 10 ml of ddH2O. Five μmoles of
each drug was added to 1 ml of 40% SBE-β-CD and sonicated until dissolved. In order to solubi-
lize posaconazole and itraconazole, the drug-SBE-β-CD suspension was acidified to pH 2 by the
addition of 15% HCl and then sonicated.
Validation of azole inhibitors for amoebicidal activity
To determine EC50 values, conazoles were tested for dose-response against N. fowleri tropho-
zoites axenically cultured in Nelson’s medium supplemented with 10% fetal bovine serum at
37˚C;[70] all the experiments were performed in triplicate using trophozoites harvested during
the logarithmic phase of growth.[71] Drug concentration ranges of 0.4–50 μM and 0.008–
25 μM in 0.2% SBE-β-CD were generated by transferring 0.5 μl of serially diluted compounds
to a corresponding well of the 96-well plate followed by addition of 99.5 μl of N. fowleri tropho-
zoites (10,000 amoebae). Assay plates were incubated for 48 h and cell viability was determined
by the CellTiter-Glo Luminescent Cell Viability Assay.[26, 71] The experiments using
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trophozoites were conducted in a biosafety cabinet following the BSL2 procedures as specified
in the UCSD Biosafety Practices Guidelines.
Ultrastructural analysis by transmission electron microscopy (TEM)
N. fowleri trophozoites (2x106) were treated with posaconazole at 0.2 μM, for 24 h and 48 h,
washed with PBS and then fixed overnight at 4˚C in modified Karnovsky’s fixative (2.5% glu-
taraldehyde and 2% paraformaldehyde in 0.1 M sodium phosphate, pH 7.2).[72] 0.1% DMSO-
treated controls were simultaneously processed. The samples were then post-fixed for 1 hour
with 1% osmium tetroxide in 0.15 M sodium cacodylate, pH 7.4, dehydrated with an ascending
series of ethyl alcohol and propylene oxide, and finally embedded in an Epon resin (Scipoxy
812, Energy Beam Sciences). Thin sections (50–60 nm) were cut using Leica UCT ultramicro-
tome, mounted on the Formvar and carbon-coated copper grids, and counterstained for 5 min
with 2% uranyl acetate followed by Sato’s lead stain for 1 min. Naegleria thin sections were
examined using a Tecnai G2 Spirit BioTWIN transmission electron microscope (TEM)
equipped with an Eagle 4k HS digital camera (FEI, Hilsboro, OR).
GC-MS analysis of the Naegleria sterols
N. fowleri sterols were analyzed by the use of GC-MS, wherein the lipids extracted from N. fow-
leri trophozoites grown in the presence of a vehicle or inhibitor at concentrations that produce
ultrastructural changes without destroying a parasite cell, were separated by gas chromatogra-
phy and subsequently analyzed by electron-ionization mass-spectrometry (EI). 2x107 or 5x107
trophozoites per sample were treated with 0.1% DMSO alone or 0.2 μM posaconazole dis-
solved in DMSO. AmpB, a drug with a different mechanism of action, was used as a negative
control at 0.2 μM. To avoid parasite death, drug exposure was terminated after 24 h when the
amoebae were pelleted by centrifugation, washed three times with PBS (3x10 ml) and, finally,
2 ml of chloroform/methanol 2:1 solution was added to the cell pellet. The organic solvents
were evaporated under N2 flow, and the pellet was incubated for 24 h with 3 ml chloroform.
Polar molecules were removed by several extractions with water (3x10 ml). The organic solvent
was then subsequently changed to chloroform/methanol 9:1 and then acetonitrile (3 ml each)
through evaporation under N2 flow; each step followed by triple washes in water as described
above.
Extracted sterols were either directly analyzed as free sterols, or first derivitized with TMS
group. For free sterol analysis, extracted dry sterols were re-dissolved in chloroform (100 μl)
and 2 μl of each sample were injected into the analytical column of the Agilent 6890 gas chro-
matograph (the inject port temperature was controlled at 250˚C), coupled to a 5973 mass
selective detector (MSD). The sterols were separated using a ZB5 capillary column (30m X
250um X0.25um) with helium carrier gas flow rate set at 1.2 ml/min and temperature profile
beginning at 170˚C for 1 min, then increased by 20˚C/min to 280˚C, and then hold at 280˚C
for 20 min. The mass spectrometer scanned m/z 50−500 during the course of analysis. The
sterols were identified by comparing the GC retention time to that of the internal cholesterol
[73] and the fragmentation patterns to that of the authentic standards and the NIST (2008)
mass spectral library. A forward and reverse match score of 800 and above was considered a
correct match. The sterols were quantified based on the total ion current peak areas of each
sterol.
For chemical derivatization, extracted dry sterols were dissolved in 30 μl of hexane and
70 μl of N,N-bis(trimethylsilyl)-2,2,2-trifluoroacetamide (BSTFA), and incubated for 2 h at
37˚C. Three microliters of the TMS-derivatized lipid mixture was injected directly into an Agi-
lent 7820A gas chromatography system coupled to a mass selective detector. The inject port
CYP51 is essential enzyme in Naegleria fowleri trophozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006104 December 28, 2017 17 / 24
temperature was controlled at 250˚C, the helium carrier gas flow rate was set at 13 ml/min.
The lipids were separated on the analytical column using a temperature profile that begins at
200˚C for 3 min, increases by 15˚C/min to 270˚C, and then holds at 270˚C for 30 min, finish-
ing with post run 280˚C 4 min. The mass spectrometer scanned m/z 50−750 during the course
of analysis.
NfCYP51 expression and purification
NfCYP51, codon-optimized for bacterial expression, had a coding sequence with 34 N-termi-
nal membrane anchoring residues replaced with the MAKKTSSKGKL to increase recombi-
nant protein recovery during purification. (S1 Data). This construct was generated
synthetically (GenScript) and cloned into the pCW-LIC expression vector obtained from the
non-profit plasmid repository (Addgene, Cambridge, MA). NfCYP51 was expressed in DH5α
E. coli strain co-transformed with the pGro7 plasmid (Takara) carrying GroEL/ES chaperones
with induction by 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 40–48 hours at
25˚C. All purification steps were carried out at 4˚C. Cells were pelleted, re-suspended in the
lysis buffer (50 mM K-PO4, pH 8.0; 100 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT
and 0.5 mM PMSF) and then disrupted using the fluid processor Microfluidics M-110P
(Microfluidics Inc.). Non-ionic detergent CHAPS was added to 0.5% and cell lysate was incu-
bated for 30 min prior to centrifugation. The crude extract was separated from cell debris.
Cleared lysate was loaded to a Ni-NTA column and after a series of washes NfCYP51 was
eluted by increasing the imidazole concentration from 0 to 500 mM. Fractions containing
NfCYP51 were pooled and passed through Q-Sepharose and then S-Sepharose (GE Healthcare
Life Sciences). NfCYP51 flowed-through both ion exchange columns was then bound to
hydroxyapatite (HAP) column (BioRad) and eluted from it in the gradient of K-PO4 concen-
trations from 0.02 M to 0.8 M supplemented with 10% glycerol, 0.5 mM EDTA and 1 mM
DTT. Fractions containing pure NfCYP51 were pooled, concentrated, aliquoted and frozen at
-80˚C.
UV-vis spectroscopy of NfCYP51
Recombinant NfCYP51 was characterized spectrally for integrity of the heme prosthetic group
and for substrate and inhibitor binding. All spectra were recorded using a Cary 1E (Varian)
dual beam UV-visible spectrophotometer. Purified NfCYP51 was diluted to 3.5 μM in 50 mM
K-PO4 (pH 7.4) and 10% glycerol buffer and allowed to equilibrate to room temperature for 10
min prior to readings. Spectra were recorded from 250–700 nm for the ferric and dithionite
reduced ferrous NfCYP51 with buffer in the reference cuvette. The CO difference spectrum
was recorded by splitting dithionite reduced ferrous NfCYP51 into the sample and reference
cuvettes. A baseline was recorded and CO was bubbled into the sample cuvette, after which the
difference spectrum was recorded. The concentration of NfCYP51 was calculated using the
extinction coefficient ε450 = 91 mM
-1cm-1.
Spectral binding titrations were performed at 25˚C using 0.5 μM NfCYP51 for conazole
and 0.2 μM for 31-norlanosterol. All conazoles with the exception of itraconazole were dis-
solved in 40% SBE-β-CD and then diluted to 100 μM stocks in 0.8% SBE-β-CD. Itraconazole
was dissolved in DMSO. 31-Norlanosterol was dissolved in 20% M-β-CD and diluted to
100 μM. For each titration 2 ml of NfCYP51 was split equally for the reference and sample
cuvettes with ligand or inhibitor being added to the sample cuvette while vehicle alone was
added to the reference cuvette, with the total added volume being less than 1% of the total vol-
ume. Spectra were recorded from 350 to 500 nm. A binding isotherm for 31-norlanosterol was
generated by plotting the absorbance minimum subtracted from the absorbance maximum as
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function of drug concentration. The spectral dissociation constant KD was estimated using the
Curve Fitting Tool in MATLAB (MathWorks, Natick, MA) by fitting the binding isotherm
using the hyperbolic Michaelis-Menten equation ΔA = ΔAmax[L]/(KD+[L]) or the quadratic
Morrison equation ΔA = (ΔAmax / 2[E])((KD + [L] + [E])—((KD + [E] + [L])
2–4[E][L])0.5)
where ΔA is the difference between absorbance maximum and minimum, ΔAmax is the extrap-
olated maximum absorbtion difference, [L] is the ligand concentration and [E] is the enzyme
concentration.
Crystallization and x-ray structure determination
Prior to crystallization, NfCYP51 was diluted to 0.5 mM by mixing with 0.6 mM inhibitor
added to the desired volume of water from the 10 mM or 100 mM stock solutions in DMSO,
depending on compound solubility. Screening of crystallization conditions for each inhibitor
complex was performed using commercial high-throughput screening kits available in deep-
well format (Hampton Research or Qiagen), a nanoliter drop-setting Mosquito robot (TTP
LabTech) operating with 96-well plates, and a hanging drop crystallization protocol. For dif-
fraction quality, crystals were further optimized in 96-well plates configured using the Dragon-
fly robot (TTP LabTech) and the Designer software (TTP LabTech). All crystals were
harvested from the narrow grid of crystallization conditions: 30–33% PEG MME 550, 30 mM
CaCl2, 0–4% Jeffamine M-600, 0.1 M bis-Tris propane, pH 7.1–7.5.
Diffraction data were collected at 100–110 K at beamline 8.3.1, Advanced Light Source, Law-
rence Berkeley National Laboratory, USA. Data indexing, integration, and scaling were con-
ducted using XDS.[74] The high-resolution crystal structure of the NfCYP51-posaconazole
complex was determined by molecular replacement using as a search model T. cruzi CYP51,
PDB ID 2X2N. The initial model was built using the BUCCANEER[75, 76] and COOT[77] pro-
grams. Refinement was performed by using REFMAC5 software.[76, 78] The newly determined
crystal structure (PDB ID 5TL8) was subsequently used for other NfCYP51-conazole complexes
reported in this work. Data collection and refinement statistics are shown in Table 4.
Accession codes. The atomic coordinates and structure factors (5TL8, 6AY4, 6AY6,
6AYB and 6AYC) have been deposited in the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/)
Supporting information
S1 Data. Recombinant NfCYP51. NfCYP51 codon-optimized DNA sequence synthetically
generated (GenScript, Piscataway, NJ) for bacterial expression—with 34 N-terminal residues
replaced with the MAKKTSSKGKL leading sequence (to inprove protein expression and puri-
fication)—and cloned into the pCW-LIC expression vector obtained from the non-profit plas-
mid repository (Addgene, Cambridge, MA).
(DOCX)
S1 Fig. Gas chromatography separation of the total sterol fractions extracted from N. fow-
leri trophozoites. Chromatogram fragments from the TMS-derivatized DMSO-, posacona-
zole- and Amphotericin B-treated N. fowleri lipid extracts are shown. Peaks are labeled
according to Table 2. The sterol identities were assigned based on relative chromatographic
behavior, the characteristic molecular masses and electron ionization (EI) fragmentation pat-
terns by comparing them to the authentic standards and the NIST (2008) mass spectral library.
In contrast to posaconazole, Amphotericin B, a drug with a different mechanism of action
used as a negative control, did not perturb the native sterol pattern.
(TIF)
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S2 Fig. Flipping of the 2,4-dichlorophenyl moiety of itraconazole evidenced by electron
density. Itraconazole in a single confirmation (yellow sticks) is shown in the fragment of the
2.6 Å 2Fo-Fc electron density map countered at 1.0 σ (cyan mesh) overlapped with a fragment
of the Fo-Fc electron density countered at -3.0 σ (red mesh). “Negative” peak at 2-chloro-sub-
stituent suggests a possibility of partial occupancy of this site due to flipping of the 2, 4-dichlor-
ophenyl moiety of itraconazole. Heme is shown in van der Waals spheres. Heteroatoms are
colored according chemical elements: oxygen–red, nitrogen–blue, chlorine–green, iron–
ochre.
(PNG)
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